strong, reaffirms targets (trading +1.8%) • Thomas Cook O3 revs inline, EBIT miss, big net debt improvement, confident outlook (trading +1.3%) • AstraZeneca Q2 revs & EBIT inline, EPS ex-items beats, overall outlook unchanged (trading -0.50%) • Arkema O2 revs & EBITDA inline, sees similar market conditions